The underlying problem is that the FDA has little ability to enforce these commitments, short of withdrawing approval for the drug an outcome that may not serve the public health well. The great majority of post-marketing studies address safety issues, at least in part, so patients and physicians are denied critical safety information when these studies are not completed in a timely fashion. Peter Lurie